Compare NBY & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NBY | BX |
|---|---|---|
| Founded | 2000 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 116.4B |
| IPO Year | 2007 | 2007 |
| Metric | NBY | BX |
|---|---|---|
| Price | $1.18 | $109.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $169.50 |
| AVG Volume (30 Days) | 818.4K | ★ 9.0M |
| Earning Date | 03-31-2026 | 04-16-2026 |
| Dividend Yield | N/A | ★ 4.18% |
| EPS Growth | ★ 35.42 | 6.91 |
| EPS | 0.76 | ★ 3.87 |
| Revenue | $370,000.00 | ★ $14,450,265,000.00 |
| Revenue This Year | $23.91 | $14.56 |
| Revenue Next Year | $32.05 | $21.82 |
| P/E Ratio | ★ $1.59 | $29.32 |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $0.43 | $101.73 |
| 52 Week High | $19.95 | $190.09 |
| Indicator | NBY | BX |
|---|---|---|
| Relative Strength Index (RSI) | 42.06 | 40.79 |
| Support Level | $0.99 | $103.41 |
| Resistance Level | $1.36 | $165.14 |
| Average True Range (ATR) | 0.18 | 4.27 |
| MACD | 0.11 | 1.41 |
| Stochastic Oscillator | 8.11 | 57.91 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Blackstone is the world's largest alternative-asset manager with $1.242 trillion in total asset under management, including $906.2 billion in fee-earning assets under management, at the end of September 2025. The company operates with scale in each of its major product lines: private equity (26% of fee-earning AUM and 33% of base management fees), real estate/real assets (31% and 35%), private credit (34% and 25%), and other alternatives (9% and 7%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).